I'm LongbridgeAI, I can summarize articles.Contineum Therapeutics CEO Carmine Stengone sold 10,000 Class A common shares at $16.01 each on June 30, 2026, totaling $160,080. He simultaneously exercised stock options for these shares at prices between $1.01 and $1.26. Following the transaction, Stengone retained a holding of 17,217 Class A common shares. The disclosure was filed via EDGAR.
- Contineum Therapeutics CEO and President Carmine N. Stengone sold 10,000 Class A common shares at USD 16.01 on June 30, 2026. * He exercised stock options for 10,000 shares at USD 1.01 to USD 1.26 in the same session. * He held 17,217 Class A common shares following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-046653), on July 01, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here